Teva Pharmaceutical Industries (NYSE:TEVA) has drawn fresh attention after its recent trading performance, with the share price closing at US$34.22 as investors reassess the business and its earnings profile.

While the latest 1 day share price return of 0.32% decline looks minor in isolation, Teva Pharmaceutical Industries has posted a 30 day share price return of 7.58% and a 90 day share price return of 38.15%, alongside a 1 year total shareholder return of 104.42%. Taken together, these figures point to strong momentum over both shorter and longer horizons as investors reassess its earnings profile and risk outlook.

If Teva’s recent run has you thinking about where else the market is finding growth, it could be worth scanning our screener of 27 healthcare AI stocks as another way to spot opportunities in healthcare related themes.

With Teva trading at US$34.22, a price target of about US$38.05 and an indicated intrinsic discount of roughly 42%, the real question is whether you see an undervalued turnaround story here or a market already pricing in future growth.

Most Popular Narrative: 9.8% Undervalued

Teva Pharmaceutical Industries' most followed narrative pegs fair value at about $37.95, a touch above the last close at $34.22. This frames the recent rally through a long term earnings and cash flow lens.

The accelerating launch cadence of biosimilars (with 8 launches targeted through 2027 and a goal to double biosimilar revenue), backed by favorable regulatory trends increasing biosimilar adoption in major markets, should unlock incremental, higher-margin revenue streams and offset headwinds from traditional generics, powering long-term EBITDA growth.

Curious how that fair value is built? The narrative leans on modest top line expansion, a step change in profitability, and a richer earnings multiple. The tension between slow headline revenue forecasts and higher margin expectations is doing a lot of the heavy lifting. If you want to see exactly how those assumptions stack up year by year, the full narrative lays it out in detail.

Result: Fair Value of $37.95 (UNDERVALUED)

However, the story could change quickly if debt near US$15b constrains investment or if key branded drugs face pricing pressure and slower than expected uptake.

Another View: Earnings Multiple Sends a Different Signal

Here is the catch. While the fair value model frames Teva Pharmaceutical Industries as trading at a discount, the current P/E of 28.3x sits above the US Pharmaceuticals average at 19.6x, the peer average at 20.6x, and even its own fair ratio of 25.6x. Is the market already paying up for this story?

Next Steps

Does this story feel more optimistic or cautious to you? The market is weighing both risks and rewards here, so act quickly, review the full picture, and see the 3 key rewards and 2 important warning signs that stand out most for you.

Ready to uncover your next idea?

If this Teva story has you thinking bigger, do not stop here. The screener can quickly surface fresh ideas that fit the way you like to invest.

• Target resilient cash generators by reviewing our 54 high quality undervalued stocks that combine earnings quality with price tags some investors might be overlooking.
• Strengthen your portfolio’s core by focusing on companies in the solid balance sheet and fundamentals stocks screener (43 results) that prioritize financial stability and fundamentals.
• Get ahead of the crowd by scanning a screener containing 23 high quality undiscovered gems before they sit firmly on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.